SBIR Phase I: Selection and Storage of Cord Blood Stem Cells in a Novel Bioreactor

* 9760236 Pykett 这个小企业创新研究I期项目将研究一种新型三维生物材料Cellfoam对脐带血（CB）中存在的造血祖细胞（HPCS）进行预选、扩增、冷冻保存和扩增的能力。 来自NSF I期奖的初步数据显示，在没有外源性细胞因子的Cellfoam中培养的CD 34 + HPC扩增8-10倍，同时保持其活力和多能性。 IIPC可以在Celifoam中冷冻保存，解冻，再培养，并用逆转录病毒载体有效转导。 我们建议研究Cellfoam的一种新应用：集成的预选，扩增，冷冻保存和转导CB HPCS。 我们将利用来自合并CB样品的未分级、Ficoll纯化或CD 34选择的制备物的细胞来评价在不含细胞因子的Cellfoam中预培养长达四周并在相同单位中冷冻保存一个月的细胞的存活、表型和多能性。 我们还将检查解冻的HPC在三周内的逆转录病毒转导。 通过使用不同的CB馏分，我们可以分离新的，关键的HPCS子集。 这项工作将促进Cellfoam系统的商业化，这是有史以来第一个用于CB HPC的集成选择、存储和修改系统，HPC银行市场预计在未来十年内每年超过6亿美元。 ***

*** 9760236 Pykett This Small Business Innovation Research Phase I project will examine the ability of a novel three-dimensional biomaterial, Cellfoam, to pre-select, expand, cyopreserve and transduce hematopoietic progenitor cells (HPCS) present in cord blood (CB). Preliminary data from NSF Phase I award DMI-9661006 show that CD34' HPCs cultured in Cellfoam without exogenous cytokines are expanded 8-10 fold while maintaining their viability and multipotency. IIPCs can be cryopreserved in Celifoam, thawed, re-cultured, and transduced efficiently with a retroviral vector. We propose to examine a novel application of Cellfoam: the integrated pre-selection, expansion, cryopreservation and transduction CB HPCS. We will utilize cells from either unfractionated, Ficoll purified or CD34' selected preparations of pooled CB samples to evaluate the survival, phenotype and multipotency of cells pre-cultured in Cellfoam without cytokines for up to four weeks and cryopreserved in the same units for one month. We will also examine the retroviral transduction of thawed HPCs over three weeks. By using different CB fractions we may isolate novel, critical subsets of HPCS. This work will facilitate commercialization of Cellfoam systems for the first-ever integrated selection, storage and modification system for CB HPCs in an HPC banking market anticipated to exceed US $600 million annually in the next decade. ***